A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Complete Title: A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors

Trial Phase: I

Investigator: Lisa Tachiki

This study will test the safety of a drug called SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if SGN-BB228 is safe and if it works to treat solid tumor cancers.

Keywords:

Mesothelioma
Pancreatic Cancer
Lung Carcinoma, Non-Small-Cell (NSCLC)
Colorectal Neoplasms
Lymphoma, T-Cell, Cutaneous

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.